International Journal of Hematology

, Volume 106, Issue 4, pp 562–572 | Cite as

Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma

  • Masaki Ri
  • Kosei Matsue
  • Kazutaka Sunami
  • Chihiro Shimazaki
  • Akio Hayashi
  • Yoshinori Sunaga
  • Toru Sasaki
  • Kenshi Suzuki
Original Article


To evaluate the efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells (HSCs) for autologous transplantation in Japanese patients with multiple myeloma (MM). In a randomized study, patients received G-CSF (filgrastim, 400 µg/m2/day) for 4 days prior to the first dose of plerixafor. Starting on Day 4 evening and for up to 4 days, patients received either plerixafor (240 µg/kg/day) + G-CSF group (PG group) or G-CSF alone (G group). Daily apheresis started on Day 5 for up to 4 days, or until ≥6 × 106 CD34+ cells/kg were collected. A total of 7 patients were randomized in each treatment group. Five patients in PG group and no patients in G group achieved a collection of ≥6 × 106 CD34+ cells/kg in ≤2 days of apheresis [difference of 71.4% (90%CI 29–100%)]. These results were supported by the shorter median time to collect ≥6 × 106 CD34+ cells/kg (2 days in PG group; no patient in G group). The incidence of treatment emergent adverse events (TEAEs) was higher in PG group than in G group. Plerixafor was well tolerated, and effective for the mobilization/collection of peripheral HSCs for autologous transplantation in Japanese patients with MM.


Plerixafor G-CSF Multiple myeloma Stem cell Apheresis 



Financial support for this study was provided by Sanofi K.K., Tokyo, Japan. Medical writing support was provided by Honyaku Center Inc. and funded by Sanofi K.K. All authors agreed to the content of the manuscript.

Compliance with ethical standards

Conflict of interest

M. Ri has received grants from Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, and has received honoraria from Celgene K.K. and Janssen Pharmaceutical K.K. K. Sunami has received research funding from Sanofi K.K., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., and has received honoraria and research funding from Celgene K.K. C. Shimazaki has received consulting fees from Fujimoto Pharmaceutical and Ono Pharmaceutical Co., Ltd. and has received speaking fees from Celgene K.K. and Janssen Pharmaceutical K.K. A. Hayashi, Y. Sunaga and T. Sasaki are employees of Sanofi K.K. The other authors have no conflicts of interest to declare.


  1. 1.
    Japanese society of Hematology, clinical practice guideline. (in Japanese). Accessed March 2016.
  2. 2.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma (V.2.2010). Fort Washington, PA: NCCN. 2010.Google Scholar
  3. 3.
    Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Group Myelome-Autogreffe, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Sung AD, Grima DT, Bernard LM, Brown S, Carrum G, Holmberg L, et al. Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transpl. 2013;48:1444–9.CrossRefGoogle Scholar
  6. 6.
    Morgan SJ, Seymour JF, Grigg A, Matthews JP, Prince HM, Wolf MM, et al. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia. 2004;18:1034–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transpl. 1996;17:937–41.Google Scholar
  8. 8.
    Gertz MA. Current status of stem cell mobilization. Br J Haematol. 2010;150:647–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Hübel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, Cooper S, et al. Leukocytosis and Mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther. 2004;1:165–72.CrossRefPubMedGoogle Scholar
  11. 11.
    Genzyme, Ltd. Summary of product characteristics for Mozobil. Accessed March 2016.
  12. 12.
    Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transpl. 2000;26:471–81.CrossRefGoogle Scholar
  13. 13.
    Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transpl. 1998;4:84–92.CrossRefGoogle Scholar
  14. 14.
    DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.PubMedGoogle Scholar
  15. 15.
    Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol. 2004;125:605–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Toor AA, Ayers J, Strupeck J, Parthasarathy M, Creech S, Rodriguez T, et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol. 2004;124:769–76.CrossRefPubMedGoogle Scholar
  17. 17.
    To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530–40.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  1. 1.Department of Hematology and OncologyNagoya City University HospitalNagoyaJapan
  2. 2.Department of Hematology and OncologyKameda Medical CenterChibaJapan
  3. 3.Department of HematologyNational Hospital Organization Okayama Medical CenterOkayamaJapan
  4. 4.Department of HematologyJapan Community Health care Organization Kyoto Kuramaguchi Medical CenterKyotoJapan
  5. 5.Sanofi K.K.TokyoJapan
  6. 6.Department of HematologyJapanese Red Cross Medical CenterTokyoJapan

Personalised recommendations